Parexel and Japanese Foundation for Cancer Research Collaborate to Boost Oncology Clinical Trials in Japan

by Sinead Huang
Share To

Parexel, a prominent global clinical research organization (CRO), and the Japanese Foundation for Cancer Research (JFCR) have unveiled a strategic alliance aimed at accelerating access to oncology clinical trials in Japan. The collaboration seeks to leverage the strengths of both organizations to enhance patient participation in cancer research.

Related article: Lokavant Secures $8 Million Investment from Mitsui to Expand Clinical Trial Intelligence Across Asia-Pacific

JFCR’s Integration into Parexel’s Global Site Alliance Network

As a key component of the agreement, JFCR will become an integral part of Parexel’s Global Site Alliance network. This move designates JFCR as a preferred site for conducting oncology clinical trials, opening up increased opportunities for Japanese patients to engage in cancer research initiatives. By joining forces with JFCR, Parexel aims to streamline patient recruitment and study initiation processes by aligning protocols with Japan’s standard of care and regulatory requirements.

Shigehiro Miki, Parexel Corporate Vice President, and General Manager of Japan emphasized the anticipated rise in cancer incidence in Japan, aligning with global trends. The strategic collaboration with JFCR is driven by a shared commitment to eliminate barriers and facilitate Japanese patients’ access to potentially transformative treatments. The alliance aims to contribute significantly to overcoming challenges in oncology research in Japan.

Patients-First Focus and Global Clinical Innovation

Parexel’s Site Alliance Network, comprising over 480 sites with approximately 21,000 investigators worldwide, plays a pivotal role in the alliance’s strategy. This network is tailored to provide a comprehensive and strategic approach to address critical challenges in the clinical trial pathway. The collaboration with JFCR is an extension of Parexel’s Patients-First focus, reflecting the organization’s dedication to driving clinical innovation, especially in key therapeutic areas like oncology, across the Asia/Pacific region. The alliance builds upon Parexel’s existing relationships with leading sites in the region, reinforcing its commitment to advancing cancer care options and research.

Parexel and JFCR’s strategic alliance signifies a unified effort to advance cancer research in Japan, ultimately benefiting patients and contributing to global oncology knowledge. By integrating JFCR into Parexel’s Global Site Alliance network, the collaboration aims to enhance the efficiency of clinical trials, address the rising cancer incidence, and align protocols with Japan’s healthcare standards. This partnership exemplifies a commitment to patients, clinical innovation, and the shared goal of conquering cancer on a global scale.

© All rights reserved. Collaborate with us:
Related Post
ASCO 2024: Covering Skin Cancer, Bispecific Antibody Treatment, TIGIT-Targeted Drugs, Radiotherapy and More
Major Cancer Research Publications at the 2024 American Society of Clinical Oncology Annual Meeting
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Company Presentations at BIO 2024 Inspire Partnering
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
BIO Releases DEI Survey in Partnership with Korn Ferry
Advancing Healthcare Accessibility and Sustainable Development
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
Scroll to Top